Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17450401 | 0.89 | PGR (0.45) | PGRDRD2DRD1DRD5CASP1 | |
| SCHEMBL7059446 | 0.89 | PGR (0.45) | PGRDRD2DRD1DRD5CASP1 | |
| SCHEMBL3862168 | 0.84 | CHRM4 (0.40) | DRD2DRD1GRIN2BBRD4ATAD2 | |
| SCHEMBL8223471 | 0.78 | DRD2 (0.39) | DRD2DRD1DRD5GRIN2BCASP1 | |
| SCHEMBL7442811 | 0.78 | ESR2 (0.54) | PGRDRD2GRIN2BHSD17B10 | |
| SCHEMBL12548647 | 0.78 | DRD2 (0.39) | DRD2DRD1DRD5GRIN2BCASP1 | |
| SCHEMBL3439729 | 0.78 | DRD2 (0.39) | DRD2DRD1DRD5GRIN2BCASP1 | |
| Hydrochloric Acid SCHEMBL1947316 | 0.76 | DRD2 (0.38) | DRD2DRD1DRD5GRIN2BCASP1 | |
| SCHEMBL12548674 | 0.76 | DRD2 (0.41) | DRD2DRD1DRD5GRIN2BCASP1 | |
| SCHEMBL22547286 | 0.76 | SRD5A1 (0.45) | PGRGFRA3RETGRIN2BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134656-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | 上海壹典医药科技开发有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022006548-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-1745047-B1 | PYRAZOLO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE ADENOSINE-A2A- RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-2021327-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| CN-1052224-C | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | PGR 1439/4885GFRA3 2607/4885RET 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.